Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 2Polycythemia Vera 1Lymphoma 1Leukemia, Myeloid, Acute 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cytarabine 89Daunorubicin 45Azacitidine 43Idarubicin 27venetoclax 26fludarabine 26Etoposide 25Cyclophosphamide 25Mitoxantrone 22Decitabine 19Busulfan 19Methotrexate 16Gemtuzumab 14Granulocyte Colony-Stimulating Factor 12Whole-Body Irradiation 10Peripheral Blood Stem Cell Transplantation 10Melphalan 10gilteritinib 9Filgrastim 9fludarabine phosphate 8Tacrolimus 8Mycophenolic Acid 8Cyclosporine 8Tretinoin 7Radiotherapy 7Drug Therapy 7Observation 6Homoharringtonine 6Antilymphocyte Serum 6quizartinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myeloid, Acute × Interferons × Clear all
NCT06802718 2025-01-31

Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

Peking University People's Hospital

Phase 3 Recruiting
96 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡